• LAST PRICE
    0.9895
  • TODAY'S CHANGE (%)
    Trending Down-0.0025 (-0.2520%)
  • Bid / Lots
    0.9815/ 1
  • Ask / Lots
    0.9896/ 6
  • Open / Previous Close
    0.9866 / 0.9920
  • Day Range
    Low 0.9800
    High 1.0150
  • 52 Week Range
    Low 0.5723
    High 2.1300
  • Volume
    139,936
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.992
TimeVolumeXFOR
09:32 ET25900.988118
09:34 ET21000.985
09:36 ET15560.985
09:38 ET52350.9897
09:39 ET36000.9882
09:41 ET259001.015
09:43 ET1131.015
09:45 ET42781.005
09:48 ET33001.01
09:52 ET2001
09:54 ET1451.0001
09:56 ET2001
09:57 ET352500.9957
09:59 ET36380.9957
10:03 ET24300.983
10:10 ET55560.9863
10:12 ET1000.98
10:14 ET189040.98735
10:17 ET1000.9899
10:19 ET31000.9893
10:24 ET1000.9898
10:26 ET2000.9885
10:28 ET2000.9885
10:30 ET2000.9885
10:32 ET5940.9898
10:33 ET4500.9877
10:35 ET1000.9887
10:37 ET1000.9898
10:39 ET19370.99
10:42 ET3000.9899
10:44 ET41850.9872
10:50 ET41210.9895
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXFOR
X4 Pharmaceuticals Inc
171.3M
-1.4x
---
United StatesACHV
Achieve Life Sciences Inc
168.3M
-3.8x
---
United StatesINMB
INmune Bio Inc
168.0M
-4.1x
---
United StatesELEV
Elevation Oncology Inc
176.5M
-2.5x
---
United StatesOTLK
Outlook Therapeutics Inc
179.5M
-0.6x
---
United StatesGALT
Galectin Therapeutics Inc
162.8M
-3.4x
---
As of 2024-06-18

Company Information

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Contact Information

Headquarters
61 NORTH BEACON STREET, 4TH FLOORBOSTON, MA, United States 02134
Phone
857-529-8300
Fax
302-655-5049

Executives

Non-Executive Independent Chairman of the Board
Michael Wyzga
President, Chief Executive Officer, Secretary, Director
Paula Ragan
Chief Financial Officer, Treasurer, Corporate Secretary
Adam Mostafa
Chief Operating Officer
Mary Dibiase
Chief Scientific Officer
Arthur Taveras

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$166.6M
Revenue (TTM)
$0.00
Shares Outstanding
167.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.40
EPS
$-0.70
Book Value
$0.31
P/E Ratio
-1.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.